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LONG-LASTING ANTI-TUMOR IMMUNITY INDUCED BY THE REJECTION
OF DONOR HEMATOPOIETIC CELLS IN MIXED BONE MARROW CHIME-
RAS
Saito, T.I., Sykes, M. Massachusetts General Hospital/Harvard Medical
School, Boston, MA.
Background: Surprisingly, some patients who reject donor mar-
row grafts following nonmyeloablative HCT sustain remissions of
advanced hematological malignancies (Br J Haematol. 2005;128:
351). In murine mixed chimeras, we previously showed that recip-
ient leukocyte infusions (RLI) induced loss of donor chimerism and
anti-tumor responses against host-type tumors (Blood. 2003;102:
2300) and that T cells are necessary to achieve anti-tumor effects
(J Immunol. 2005;175:665). We now examined whether or not this
anti-tumor response demonstrates long-term memory. We at-
tempted to enhance anti-tumor effects by adding exogenous IL-15,
which promotes CD8 memory T cell survival. Methods: The A20
tumor model was used as previously described (Blood. 2003;102:
2300). Some groups received a secondary A20 challenge (105) 100
days after the ﬁrst challenge. Some groups received 5 g of IL-15
intraperitoneally, starting one week after RLI injection and every
12 h thereafter for a total of 10 doses. Spleen cells were isolated and
anti-tumor cytotoxicity was evaluated after 5 days’ coculture with
irradiated A20 cells. Results: One third of long-term survivors
(n  20) rejected a second lethal dose of A20 and survived 	200
days. In contrast, all mice in the control group that did not
previously receive RLI and received their ﬁrst tumor challenge
concurrently with the rechallenge group died, with a MST of 56
days (n  23) (P  .02). We have previously demonstrated in vitro
tumor-speciﬁc cytotoxic responses 11 weeks after ﬁrst tumor chal-
lenge. We now observed such responses even 11 months after ﬁrst
tumor challenge in some of the tumor survivors. From these
results, we speculated that memory CTL may play an important
role and hypothesized that exogenous IL-15 administration might
enhance the anti-tumor effect of RLI, since it promotes generation
and maintenance of memory T cells. Indeed, we observed in-
creased tumor-free survival in mice that received RLI and IL-15
(n  14) compared to recipients of RLI alone (n  14) (MST 64
versus 48 days respectively, P .03). Conclusion: Together, these
data suggest that RLI therapy can evoke long-term anti-tumor
immunity and that the anti-tumor response may be enhanced by
administration of exogenous IL-15, reinforcing the potential of
RLI therapy to provide a new HCT strategy lacking the risk of
graft-versus-host disease.
136
COMPARISON OF 2 GVHD PROPHYLAXIS REGIMENS IN NONMYELO-
ABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) WITH FLUDARABINE AND LOW DOSE TBI AS CONDITION-
ING: FAVORABLE OUTCOME WITH ADDITION OF SHORT COURSE OF
METHOTREXATE
Koh, L.-P.1, Tai, B.-C.2, Koh, M.B.C.1, Ng, H.-Y.3, Hwang, W.Y.K.1,
Linn, Y.-C.1, Goh, Y.-T.1, Fook Chong, S.M.C.4, Ng, H.-J.1,
Chuah, C.T.H.1, Loh, Y.S.M.1, Tan, D.C.L.1, Tan, P.H.C.5 1. De-
partment of Hematology, Singapore General Hospital, Singapore; 2.
Center for Molecular Epidemiology, Department of Community, Occu-
pational and Family Medicine, National University of Singapore, Sin-
gapore; 3. Department of Pharmacy, Singapore General Hospital, Sin-
gapore; 4. Department of Clinical Research, Singapore General Hospital,
Singapore; 5. Mount Elizabeth Hospital, Singapore.
The development of nonmyeloablative HSCT has extended the
potential curative treatment option of allografting to patients in
whom it was previously contraindicated due to advanced age or
comorbidity. Acute grade II-IV GVHD, albeit lower as compared
to ablative HSCT, causes substantial mortality and morbidity. In
this study, we investigated the effect of 2 GVHD prophylaxis
regimens on the incidence and severity of acute GVHD in 52
patients who received NM conditioning with ﬂudarabine 90
mg/m2 and TBI 2 Gy, followed by GCSF-mobilized peripheral
blood stem cell transplant from HLA identical (n  47), 5/6
antigen-matched related (n  2), or matched unrelated (n  3)
donors. Median age of these patients was 44 years (range; 20-60)
with 75% being 	40 years old. Diagnoses include leukemia/MDS
(n  38), lymphoma/myeloma (n  6), myeloﬁbrosis (n  1),
aplastic anemia (n 7). Twenty six (50%) patients were considered
to have good risk disease (CR1, CML in ﬁrst CP, aplastic anemia,
MDS-RA). Eight (16%) failed prior autologous (n  7) or alloge-
neic (n  1) HSCT. Twenty one patients received CSA and MMF
as GVHD prophylaxis (group 1), whereas 31 patients received
additional short course IV MTX (group 2). The 2 groups did not
differ signiﬁcantly in terms of age, gender, disease risk category,
CD34 cell dose, CD3 cell dose, duration of neutropenia and
thrombocytopenia. Median follow-up was 496 days and 101 days
for group 1 and 2, respectively. The cumulative incidence of grade
II-IV GVHD was 58% and 55% for group 1 and 2, respectively
(P  .93). The cumulative incidence of grade III-IV GVHD was
53% and 29% for group 1 and 2, respectively (P  .13). There was
no statistically signiﬁcant difference in the cumulative incidence of
relapse between the two groups (24% vs 54%; P .07). Transplant
related mortality (TRM) at 3 years was signiﬁcantly higher in
group 1 (71%) as compared to group 2 (16%) (P  .0001). The
difference in grade III-IV GVHD and TRM translate into a su-
perior 3-year overall survival (49% vs 5%; P  .001) and progres-
sion-free survival (30% vs 5%; P  .0015) in group 2 as compared
to group 1. Multivariate analysis identiﬁed the addition of MTX to
GVHD prophylaxis as the only factor that has signiﬁcant impact
on the overall and progression-free survival as well as TRM. In
conclusion, this retrospective study showed that modiﬁcation of
GVHD prophylaxis is crucial in reducing the incidence of severe
GVHD and TRM, resulting in favorable outcomes in patients
undergoing NMSCT.
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OCULAR GRAFT VS. HOST DISEASE EXPERIENCE FROM MD ANDERSON
CANCER CENTER: NEWLY DESCRIBED CLINICAL SPECTRUM AND NEW
APPROACH TO THE MANAGEMENT OF STAGE III AND IV OCULAR GVHD
Kim, S.K., Couriel, D., Ghosh, S., Champlin, R. UT MD Anderson
Cancer Center, Houston, TX.
Purpose: To describe new clinical entities associated with
chronic ocular GVHD and to describe new management of stage
III (pseudomembranous/membranous conjunctivitis) and IV ocular
GVHD (stage III plus corneal epithelial sloughing) from MD
Anderson Cancer Center (MDACC).Methods:Two retrospective
reviews of post-allogeneic BMT patients from MDACC Ophthal-
mology Clinic were performed 1) between 2003-2004 for acute and
chronic ocular GVHD and 2) between 2000-2002 for stage IV
ocular GVHD. Results: There were 194 patients with the diag-
nosis of acute or chronic ocular graft vs. host disease treated at MD
Anderson Cancer Center Ophthalmology Clinic between 2003-
2004. Among them, 2 cases of episcleritis and 14 cases of superior
limbic keratoconjunctivitis (SLK) were identiﬁed. Episcleritis is a
sectoral inﬂammatory condition of tissue between conjunctiva and
sclera with 1/3 association of systemic conditions, and SLK is
idiopathic, often bilateral, chronic conjunctival inﬂammatory pro-
cess with variable remission/exacerbation course. All 14 cases of
SLK were associated with Schirmer’s 	3 mm and cicatricial con-
junctival scarring of the upper lids. There were 17 patients with
stage III ocular GVHD with pseudomembranous/membranous
conjunctival ocular GVHD: 14 patients managed with extensive
lysis and removal of membrane/pseudomembrane plus topical ste-
roid and cyclosporine experienced less ﬁbrovascular scarring/cica-
tricial changes on the lids compared to 3 patients who were man-
aged conservatively with topical medication alone. Between 2000-
2002, there were 7 stage IV ocular GVHD patients. Early and
aggressive topical steroid lead to improved healing and decreased
corneal scarring (5/7) compared to those (2/7) treated with con-
servative treatment of topical antibiotic and lubrication alone.
Clinical ﬁndings of episcleritis and SLK in chronic GVHD and the
management of stage III and IV ocular GVHD have not been
previously described in the literature. Conclusions: Inﬂammatory
ocular conditions such as SLK and episcleritis may be observed as
clinical manifestations of chronic ocular GVHD. Our observation
suggests that the management of stage III and IV ocular GVHD
with aggressive topical steroid and the removal of inﬂammatory
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tissue (membrane/pseudomembrane) may improve the rate of ep-
ithelial healing and decrease cicatricial scarring from ocular
GVHD.
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ELEVATED TNF RECEPTOR LEVELS EARLY AFTER MYELOABLATIVE
BMT PREDICT FOR GVHD AND DEATH
Levine, J.E., Yanik, G.A., Cooke, K.R., Reddy, P., Hutchinson, R.,
Krijanovski, O., McMahon, C., Whitﬁeld, J., Ferrara, J.L. University
of Michigan Cancer Center, Ann Arbor, MI.
Inﬂammatory cytokines are thought to play a signiﬁcant role in
the toxicity of allogeneic BMT. We examined the correlation of
plasma levels of TNF-
 and outcomes in 64 patients receiving
myeloablative allogeneic BMT using soluble TNF-
 receptor 1
(TNFR1) as a surrogate marker for TNF-
. Because baseline
values of TNFR1 pre-BMT ranged ﬁfty-fold between patients
(105-5876 pg/ml), all TNFR1 values post BMT were normalized
to pre-BMT baseline. We ﬁrst evaluated the relationship between
TNFR1 and GVHD. Of the 64 subjects, 36 (56%) subjects had no
GVHD and 28 (44%) had GVHD as their only serious post-
transplant complication (mean day of onset, 28 d). On day 7, when
no subject had GVHD, the mean TNFR1 ratio in subjects who
remained GVHD-free was 2.2 compared to 4.6 in those who
eventually developed GVHD (P  .003). Subjects were divided
equally into low, medium and high categories of day 7 TNFR1
ratios and had rates of eventual GVHD of 27%, 33%, and 62%,
respectively (P  .02). Seven subjects died before day 100, all from
GVHD. Day 28 TNFR1 ratios (the mean day of onset of GVHD)
correlated with mortality by day 100. The mean TNFR1 ratio on
day 28 in subjects who survived to day 100 was 3.0 compared to a
mean ratio of 10.4 in subjects who died before day 100 (P  .001).
Subjects were divided equally into low, medium and high catego-
ries of day 28 TNFR1 ratios and had rates of death by day 100 of
0%, 20%, and 29%, respectively (P  .04). Of the 28 patients who
developed acute GVHD and required treatment of the disease, 14
(50%) responded completely to high-dose steroids and 14 had
incomplete responses. In patients with complete responses TNFR1
ratios decreased, and 8 weeks later were equivalent to ratios in
patients never experiencing GVHD. By contrast, patients who did
not completely respond to high-dose steroids showed increasingly
elevated TNFR1 ratios that were signiﬁcantly different at 8 weeks
post-onset (P  .03). We conclude that post-myeloablative trans-
plant TNFR1 ratios correlate with the subsequent development of
GVHD and day 100 mortality. Subjects who develop GVHD who
respond to treatment show falling TNFR1 levels while non-re-
sponders show increasing levels. We have expanded this prelimi-
nary study to an additional 150 patients with results pending.
Further exploration of the predictive value of post-transplant
TNFR1 ratios may help develop a diagnostic test predictive of
complications days to weeks in advance of their clinical presenta-
tion.
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CYCLOSPORIN A AND MINI SHORT-TERM METHOTREXATE VERSUS
CYCLOSPORIN A AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN
PATIENTS WITH BETA THALASSEMIA MAJOR UNDERGOING ALLOGE-
NEIC BLOOD AND MARROW TRANSPLANTATION
Iravani, M., Mousavi, A., Gholibeikian, S., Bahar, B., Samiee, S.,
Ashouri, A., Eghbal, L., Ghavamzadeh, A. Hematology-Oncology &
Bone Marrow Transplantation Research Center, Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran.
In this study, we compared the effects of cyclosporine A (CsA)
alone as graft-versus-host disease (GVHD) prophylaxis versus cy-
closporine with short course methotrexate (MTX) in patients with
thalassemia who received hematopoietic stem cell transplantation
from HLA-identical siblings. One hundred forty patients were
enrolled in this study. The ﬁrst group, 50 patients (class I and II),
received CsA alone 3 mg/kg IV from day 2 to 5 followed by
12.5 mg/kg p.o. which was tapered according to the patient’s
condition. The other group of 90 (class I, II, III) patients received
the combination of CsA  MTX in which CsA was used with the
above mentioned dose and MTX was 10 mg/m2 on day 1 and 6
mg/m2 on days3 and6. Incidence of acute GVHD grade II-IV
in the CsA group was 78% and in the CsA  MTX group was
52.2%, which was statistically signiﬁcant (P  .001).There was no
signiﬁcant difference in the incidence of chronic GVHD between
two groups. The mean time to neutrophil engraftment to 0.5 
109/L was 14 and 23 days for CsA group and CsA  MTX group,
respectively (P  .001). There were no signiﬁcant differences for
platelet recovery between the two groups. Graft failure in the CsA
and CsAMTX groups was seven (14%) and nine (10%) patients,
respectively (P  .58). The 5 year overall survival (OS) and disease
free survival (DFS) was 77% and 58% in the CsA group versus
85% and 80% in the CsA MTX group, respectively. OS had no
statistically signiﬁcant differences between two groups (P  .56)
but there were signiﬁcant differences for DFS between the two
groups (P  .05). This study shows that the CsA and short term
MTX for a GVHD prophylaxis regimen can reduce the incidence
of aGVHD grade II to IV and improve the probability for survival
in patients with thalassemia major given allogeneic blood and
marrow transplantation.
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SIGNIFICANT INCREASE IN CORD BLOOD (CB) VS PERIPHERAL BLOOD
(PB) ALLOANTIGEN SPECIFIC T-REGULATORY (T-Reg) (CD4/CD25/
CTLA4) CELLS FOLLOWING ANTIGEN PRESENTING CELL (APC) IN-
DUCTION: MOLECULAR, FUNCTIONAL AND IMMUNOPHENOTYPIC
CHARACTERIZATION
Cairo, M.S., Satwani, P., Oberﬁeld, N., Vlad, G., Simpson, L.,
van de Ven, C., Chang, C. Columbia University, New York, NY.
We have demonstrated that HLA disparate (2-3 antigen) CB can
successfully be used as an alternative allogeneic (allo) cell source
and more importantly, is associated with decreased severe acute
and chronic GVHD (Cairo et al., Blood, 1997). Studies from our lab
have suggested an immaturity in CB T cell immunity in part
secondary to decreased IL-12, IL-15 and IL-18 gene expression
and protein production. However, CB T reg cells may also actively
and speciﬁcally suppress unwanted allo immune responses. In this
study we compared the functional and molecular events with the
induction of allo speciﬁc CB vs PB T-reg cells. Brieﬂy, Mutz-3
immature dendritic cells (iDC) and monocyte derived (GM-CSF/
IL-4  7 d) (m)DC were utilized for APC in vitro stimulation.
CD4, CD4/CD25 and CD4/CD25 CB and PB were puri-
ﬁed by CD4 and CD25 selection (Miltenyi, Auburn, CA). CD4/
25 proliferation was determined by in vitro priming with iDC or
mDC 1:5 ratio with 3H-thymidine in both primary and secondary
MLR reactions. T-reg suppression was measured with CD4/25/
CD4/25 iDC at a 1:1:0.1 ratio. RT-PCR was used to measure
gene expression of GITR, FoxP-3, CTLA-4, CD25, GAPDH and
ﬂow cytometry for GITR, CTLA-4, CD25 and IL-10 expression.
Naive PB CD4/25 (T-reg) signiﬁcantly suppressed CD4/
CD25 proliferation compared to CB T-reg (60% vs 10%, P 
.02). However, in the secondary MLR response CB vs PB CD4
proliferation was signiﬁcantly less with Mutz-iDC (10.5  3.3 vs
48.5  13.1  105 cpm, P  .02) suggesting a decrease in allo
response of CB vs PB CD4 T cells. Naive CB vs PB CD4/25
T-reg had similar gene expression of GITR, FoxP-3, CTLA-4 and
CD25. However, GITR protein expression was signiﬁcantly
higher in CB vs PB (11  3 vs 3.4  1.6%, P  .05). Following
Mutz-iDC induction of CD4/25, T-reg cells demonstrated sim-
ilar gene expression of CTLA-4, GITR, FoxP-3 and CD25 (3-8
fold) with CB vs PB, however, there was a signiﬁcant increase in
CB vs PB protein expression of CD25 (50  1 vs 35  2%, P 
.02) and CTLA-4 (25.2  5.5 vs 12.5  0.9%, P  .05). Further-
more, CB T-reg suppressive activity was allo-antigen speciﬁc
(Mutz-iDC vs MHC I mismatched allo-mDC: 31.5  4 vs 73 
10.5%, P  .001) and IL-10 independent. In summary, there is a
signiﬁcant increase in allogeneic speciﬁc APC induction of CB vs
PB CD25/CTLA-4/CD4 T-reg cells which may in part be
responsible for the suppression and decrease in alloantigen recog-
nition and immune response of CB CD4/CD25 T cells.
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